Insulin Syringes Market Size

ID: MRFR/Pharma/10549-HCR

128 Pages

Rahul Gotadki

October 2025

Insulin Syringes Market Research Report Information By Syringe Size (3/10 CC Syringe (0.3ml), 1/2 CC Syringe (0.5ml), 1CC Syringe (1ml), Others), By Disease (Type 1 Diabetes And Type 2 Diabetes), By End-use (Hospitals & Clinics, Homecare Settings, Others) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2035

Request Free Sample

Summary Table of Contents Segmentation Download PDF

Insulin Syringes Size

Insulin Syringes Market Growth Projections and Opportunities

The Pharmaceutical Insulin Syringes Market is not complete without it, as the market serves individuals with diabetes that require insulin. This growth is due to advancements in insulin delivery technology and an increasing number of diabetics worldwide. Managing diabetes requires pharmaceutical syringes for administering insulin accurately and safely.

One major factor contributing to the development of the Pharmaceutical Insulin Syringes Market is a rise in diabetes instances across the globe. Consequently, the bulging population of diabetic patients has led to increased demand for insulin devices such as syringes. This implies that diabetic persons can opt for pharmaceutical insulin syringes so as to self-administer them, thus enhancing glycemic control and proper control over diseases.

Pharmaceutical Insulin Syringes Market addresses different needs among diabetic populations through availability of various specifications and feature-rich syringe options. These companies are investing on ultra-thin needles, ergonomic designs and user-friendly features so that patient’s comfort improves as well as adherence. Their objective is thus met when they keep making better improvements in technology aimed at making administration more convenient so that fear among the patient reduces.

Pharmaceutical Insulin Syringe markets have grown in many geographical areas including North America, Europe, Asia Pacific etcetera. These regions have high incidents of diabetes; therefore, they have established health facilities related to diabetics control measures hence advanced care strategies towards this disease. On the other hand, there is rapid urbanization increasing prevalence rates of Diabetes Mellitus (DM) besides gaining self-awareness about DM treatment process leading to significant rise within Asia-Pacific.

A popular trend within this market involves switch from vial-and-syringe methods towards prefilled insulin injection syringe systems. These offer convenience, accuracy and safety against possible overdose or underdose thus becoming preferable over others by both patients and doctors alike who consider them effective tools for managing diabetes mellitus. Therefore, such changes have been witnessed which include shifting from vials and syringes for prefilled insulin syringes which are designed in such a way that; they make the administration of insulin injections easier and also promote patients’ adherence to their daily doses of insulin.

Competition among manufacturers of pharmaceutical insulin syringes is evidenced by numerous players involved. They concentrate on research and development so as to come up with new designs and include features that are able to meet changing customer needs. In addition, these people have partnered with health providers as well as diabetes educators who have been instrumental in teaching these patients about new technologies used in delivering insulin.

Market Highlights

Author

Rahul Gotadki

Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Get In Touch

FAQs

What is the projected market valuation of the Insulin Syringes Market by 2035?

The Insulin Syringes Market is projected to reach a valuation of 2.901 USD Billion by 2035.

What was the market valuation of the Insulin Syringes Market in 2024?

In 2024, the Insulin Syringes Market was valued at 1.844 USD Billion.

What is the expected CAGR for the Insulin Syringes Market during the forecast period 2025 - 2035?

The expected CAGR for the Insulin Syringes Market during the forecast period 2025 - 2035 is 4.2%.

Which companies are considered key players in the Insulin Syringes Market?

Key players in the Insulin Syringes Market include Becton Dickinson, Novo Nordisk, Sanofi, Eli Lilly, Terumo Corporation, Medtronic, Roche, Ypsomed, and Owen Mumford.

What are the projected revenues for Type 1 and Type 2 Diabetes segments by 2035?

By 2035, the projected revenues for Type 1 Diabetes and Type 2 Diabetes segments are expected to be 1.45 USD Billion and 1.451 USD Billion, respectively.

How do the revenues of 3/10 CC Syringes compare to 1CC Syringes in 2024?

In 2024, the revenue for 3/10 CC Syringes was 0.553 USD Billion, while 1CC Syringes also generated 0.553 USD Billion.

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Customize Report

Certified Researchers

Market Summary

As per MRFR analysis, the Insulin Syringes Market Size was estimated at 1.844 USD Billion in 2024. The Insulin Syringes industry is projected to grow from 1.922 USD Billion in 2025 to 2.901 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 4.2 during the forecast period 2025 - 2035.

Key Market Trends & Highlights

The Insulin Syringes Market is poised for growth driven by technological advancements and increasing diabetes awareness.

North America remains the largest market for insulin syringes, reflecting a robust healthcare infrastructure. The Asia-Pacific region is emerging as the fastest-growing market, fueled by rising diabetes prevalence and healthcare investments. 1CC syringes dominate the market, while 3/10 CC syringes are experiencing rapid growth due to changing patient preferences. Key market drivers include the increasing prevalence of diabetes and technological innovations in syringe design.

Insulin Syringes Market

CAGR

4.2%

Market Size & Forecast

2024 Market Size	1.844 (USD Billion)
2035 Market Size	2.901 (USD Billion)
CAGR (2025 - 2035)	4.2%
Largest Regional Market Share in 2024	North America

Major Players

Becton Dickinson (US), Novo Nordisk (DK), Sanofi (FR), Eli Lilly (US), <a href="https://www.terumo.com/newsrelease/detail/20231114/6011">Terumo Corporation </a>(JP), Medtronic (US), Roche (CH), Ypsomed (CH), Owen Mumford (GB)

Market Trends

The Insulin Syringes Market is currently experiencing notable transformations driven by various factors. The increasing prevalence of diabetes globally has led to a heightened demand for insulin delivery devices, particularly syringes. As healthcare systems evolve, there is a growing emphasis on patient-centric solutions, which has prompted manufacturers to innovate and enhance the usability of their products. Furthermore, advancements in technology are facilitating the development of more precise and user-friendly syringes, which may improve patient adherence to treatment regimens. This trend appears to be fostering a competitive landscape where companies strive to differentiate their offerings through design and functionality. In addition to technological advancements, regulatory frameworks are also shaping the Insulin Syringes Market. Governments and health organizations are implementing stricter guidelines to ensure safety and efficacy in medical devices. This regulatory scrutiny could lead to increased quality standards, thereby influencing production processes and market entry strategies. Moreover, the rising awareness of diabetes management among patients is likely to drive demand for insulin syringes, as individuals seek reliable and effective means of self-administration. Overall, the Insulin Syringes Market seems poised for growth, with various dynamics at play that could redefine its future landscape.

Technological Advancements

The Insulin Syringes Market is witnessing a surge in innovation, particularly in the development of smart syringes. These devices often incorporate features such as dose tracking and connectivity to mobile applications, which may enhance user experience and adherence to treatment protocols. As technology continues to evolve, the integration of digital health solutions into insulin delivery systems appears to be a key trend.

Regulatory Changes

Regulatory bodies are increasingly focusing on the safety and efficacy of medical devices, including insulin syringes. Stricter guidelines and quality standards are being established, which could impact manufacturing processes and market dynamics. This trend suggests that companies must adapt to comply with new regulations, potentially leading to improved product quality and patient safety.

Rising Diabetes Awareness

There is a growing awareness regarding diabetes management among patients and healthcare providers. Educational initiatives and outreach programs are likely contributing to this trend, encouraging individuals to seek effective solutions for insulin administration. As awareness increases, the demand for insulin syringes may rise, reflecting a shift towards proactive health management.

Insulin Syringes Market Market Drivers

Rising Geriatric Population

The increasing geriatric population is a significant factor influencing the Insulin Syringes Market. As individuals age, the risk of developing chronic conditions, including diabetes, escalates. The World Health Organization estimates that the number of people aged 60 years and older will reach 2 billion by 2050. This demographic shift is likely to result in a higher prevalence of diabetes among older adults, thereby driving the demand for insulin syringes. Moreover, older patients often require assistance with insulin administration, which may lead to a greater reliance on healthcare services and products. Consequently, the Insulin Syringes Market is expected to expand as healthcare systems adapt to meet the needs of this growing population segment.

Increasing Prevalence of Diabetes

The rising incidence of diabetes worldwide is a primary driver for the Insulin Syringes Market. According to recent statistics, the number of individuals diagnosed with diabetes has reached approximately 537 million, with projections indicating a potential increase to 643 million by 2030. This alarming trend necessitates the need for effective diabetes management solutions, including insulin syringes. As more patients require insulin therapy, the demand for insulin syringes is expected to grow significantly. Furthermore, the increasing prevalence of obesity, which is closely linked to type 2 diabetes, further exacerbates this situation. Consequently, healthcare providers are likely to emphasize the importance of insulin delivery systems, thereby propelling the Insulin Syringes Market forward.

Government Initiatives and Support

Government initiatives aimed at improving diabetes care and management are playing a crucial role in shaping the Insulin Syringes Market. Many countries are implementing policies to enhance access to diabetes treatment, including subsidizing the cost of insulin syringes for patients. These initiatives not only alleviate the financial burden on patients but also encourage adherence to prescribed treatment regimens. Furthermore, public health campaigns aimed at raising awareness about diabetes prevention and management are likely to increase the number of individuals seeking insulin therapy. As governments continue to prioritize diabetes care, the Insulin Syringes Market is poised for growth, driven by increased accessibility and support for patients.

Technological Innovations in Syringe Design

Technological advancements in the design and functionality of insulin syringes are transforming the Insulin Syringes Market. Innovations such as safety-engineered syringes, which reduce the risk of needlestick injuries, are gaining traction among healthcare professionals. Additionally, the introduction of pre-filled syringes and smart syringes equipped with digital tracking capabilities enhances patient compliance and monitoring. These advancements not only improve the user experience but also contribute to better health outcomes for patients. The market for insulin delivery devices is projected to grow at a compound annual growth rate (CAGR) of around 8.5% from 2023 to 2030, indicating a robust demand for innovative insulin syringes. As technology continues to evolve, the Insulin Syringes Market is likely to witness further enhancements that cater to the needs of both patients and healthcare providers.

Growing Demand for Home Healthcare Solutions

The shift towards home healthcare solutions is significantly impacting the Insulin Syringes Market. With an increasing number of patients opting for self-management of their diabetes, the demand for insulin syringes suitable for home use is on the rise. This trend is further supported by the growing availability of educational resources and training programs that empower patients to administer their insulin effectively. The convenience of home healthcare not only enhances patient autonomy but also reduces the strain on healthcare facilities. As a result, the Insulin Syringes Market is likely to experience a surge in demand for user-friendly and portable insulin delivery systems that cater to the needs of patients managing their diabetes at home.

Market Segment Insights

By Syringe Size: 1CC Syringe (Largest) vs. 3/10 CC Syringe (Fastest-Growing)

In the Insulin Syringes Market, the distribution among syringe sizes showcases the 1CC syringe (1ml) as the dominant player, capturing a significant portion of the market share due to its versatility and widespread use among diabetes patients. The 3/10 CC syringe (0.3ml), while smaller in market share, is rapidly gaining traction among users who prefer lower doses, reflecting a shifting preference towards precision and convenience in insulin management. The growth trends in this segment are largely driven by increasing diabetes prevalence and advancements in insulin delivery technology. Consumers are increasingly opting for specific syringe sizes that cater to their dosages, which has positioned the 3/10 CC syringe as the fastest-growing category. Innovations related to <a href="https://www.marketresearchfuture.com/reports/syringes-market-19219">syringe </a>design and patient education are further propelling this segment, thus influencing market dynamics favorably.

1/2 CC Syringe (Dominant) vs. Others (Emerging)

The 1/2 CC syringe (0.5ml) stands out as a dominant segment in the Insulin Syringes Market, known for its balanced capacity that appeals to a wide range of insulin-dependent patients. It offers an optimal solution for those requiring mid-range doses, ensuring both efficiency and comfort in administering insulin. In contrast, the 'Others' category includes a variety of less common syringe sizes, which while emerging, cater to niche markets and specific patient needs. This segment is growing in response to personalized medicine trends, as healthcare providers look for tailored solutions for diabetes management. As more patients seek syringes that accommodate their unique dosing requirements, the 'Others' segment is expected to gradually increase its market presence.

By Disease: Type 1 Diabetes (Largest) vs. Type 2 Diabetes (Fastest-Growing)

In the Insulin Syringes Market, Type 1 Diabetes currently holds the largest share of the market, reflecting the significant prevalence of this condition among younger patients and the increasing awareness regarding its management. The reliance on insulin therapy for Type 1 patients has fueled a steady demand for insulin syringes, ensuring that this segment remains a key component of the market landscape.

Type 1 Diabetes (Dominant) vs. Type 2 Diabetes (Emerging)

Type 1 Diabetes is characterized by the absolute dependence on insulin due to the autoimmune destruction of insulin-producing pancreatic beta cells, necessitating consistent insulin administration through syringes. This segment dominates the market driven by a higher prevalence in the pediatric population and continuous advancements in syringe technology. In contrast, Type 2 Diabetes is emerging rapidly due to lifestyle changes and increasing obesity rates. Patients often require insulin therapy as the disease progresses, which drives demand for insulin syringes. Health education and preventive measures are pivotal in managing Type 2 Diabetes, suggesting growth potential in this segment as awareness increases.

By End-use: Hospitals & Clinics (Largest) vs. Homecare Settings (Fastest-Growing)

In the Insulin Syringes Market, the end-use segment is primarily dominated by hospitals and clinics, which account for a significant portion of the overall market share. These settings benefit from high patient inflow and the need for regular insulin administration among diabetic patients, leading to sustained demand for syringes. Homecare settings are also notable, emerging rapidly due to increased patient preferences for self-monitoring and self-administration of insulin, incentivized by rising health awareness and technological advancements. The growth trends in this segment are heavily influenced by an aging population and a rise in diabetes cases globally. Additionally, the transition towards homecare settings is accelerated by convenience, patient empowerment, and technological innovations like smart insulin pens. Furthermore, hospitals continue to invest in advanced medical devices, including prefilled syringes, to enhance patient care, while homecare settings experience growth due to flexible treatment options and easier accessibility to insulin management tools.

Hospitals & Clinics (Dominant) vs. Homecare Settings (Emerging)

Hospitals and clinics remain the dominant end-users in the Insulin Syringes Market owing to their robust infrastructure and consistent patient flow, providing a stable demand for insulin delivery solutions. These facilities are equipped with trained healthcare professionals who ensure proper administration techniques, enhancing patient safety and outcomes. On the other hand, homecare settings are emerging as a significant segment, driven by patients' desire for autonomy in managing their diabetes. This growth is supported by the increasing availability of user-friendly insulin syringes and educational resources promoting self-administration. As healthcare shifts towards more personalized and accessible solutions, both segments are poised for continued evolution, with hospitals focusing on advanced therapeutic technologies and homecare embracing convenience and flexibility.

Get more detailed insights about Insulin Syringes Market Research Report 2035

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for insulin syringes, holding approximately 45% of the global share. The region's growth is driven by increasing diabetes prevalence, technological advancements in syringe design, and supportive healthcare policies. Regulatory bodies like the FDA have streamlined approval processes for innovative devices, further boosting market growth. The rising demand for home healthcare solutions is also a significant catalyst for this market. The United States is the leading country in this region, with major players like Becton Dickinson and Eli Lilly dominating the market. Canada follows as the second-largest market, benefiting from a robust healthcare system and increasing awareness about diabetes management. The competitive landscape is characterized by continuous innovation and strategic partnerships among key players, ensuring a steady supply of advanced insulin delivery systems.

Europe : Emerging Market with Growth Potential

Europe is witnessing significant growth in the insulin syringes market, holding around 30% of the global share. The increasing incidence of diabetes, coupled with an aging population, is driving demand for insulin delivery devices. Regulatory frameworks in countries like Germany and France are becoming more favorable, promoting the adoption of advanced insulin syringes. The European Medicines Agency (EMA) is actively working to enhance the approval process for innovative medical devices, which is expected to further stimulate market growth. Germany and France are the leading countries in this region, with a strong presence of key players such as Sanofi and Roche. The competitive landscape is marked by a focus on product innovation and strategic collaborations among manufacturers. The market is also influenced by the rising trend of self-administration of insulin, leading to increased demand for user-friendly and efficient syringe designs. This trend is expected to continue, driving further growth in the coming years.

Asia-Pacific : Rapidly Growing Market Segment

Asia-Pacific is emerging as a significant player in the insulin syringes market, accounting for approximately 20% of the global share. The region's growth is fueled by rising diabetes prevalence, increasing healthcare expenditure, and government initiatives aimed at improving diabetes management. Countries like India and China are witnessing a surge in demand for insulin delivery devices, supported by favorable regulatory environments that encourage innovation and accessibility. China and India are the leading markets in this region, with a growing number of local and international players entering the market. The competitive landscape is characterized by a mix of established companies and new entrants, focusing on affordability and accessibility of insulin syringes. The presence of key players like Terumo Corporation and Medtronic is enhancing the market dynamics, ensuring a steady supply of advanced products tailored to meet local needs.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa region is gradually emerging in the insulin syringes market, holding about 5% of the global share. The growth is primarily driven by increasing diabetes cases and a rising awareness of diabetes management. Governments in several countries are implementing health initiatives to improve access to diabetes care, which is expected to boost the demand for insulin delivery devices. Regulatory bodies are also working towards establishing clearer guidelines for medical devices, facilitating market entry for new products. South Africa and the UAE are the leading countries in this region, with a growing number of healthcare facilities and increasing investments in healthcare infrastructure. The competitive landscape is still developing, with both local and international players striving to capture market share. The presence of key players like Owen Mumford is helping to enhance product availability and drive innovation in insulin delivery systems, paving the way for future growth in this untapped market.

Key Players and Competitive Insights

The Insulin Syringes Market is characterized by a dynamic competitive landscape, driven by increasing diabetes prevalence and the growing demand for efficient insulin delivery systems. Major players such as Becton Dickinson (US), Novo Nordisk (DK), and Eli Lilly (US) are strategically positioned to leverage innovation and expand their market presence. Becton Dickinson (US) focuses on enhancing product offerings through technological advancements, while Novo Nordisk (DK) emphasizes partnerships to broaden its distribution channels. Eli Lilly (US) is actively pursuing digital transformation initiatives to improve patient engagement and streamline operations. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and responsiveness to market needs.

In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The Insulin Syringes Market appears moderately fragmented, with key players exerting considerable influence over market dynamics. This fragmentation allows for niche players to emerge, yet the collective strength of major companies shapes pricing strategies and product availability, creating a complex interplay of competition.

In August 2025, Becton Dickinson (US) announced the launch of a new smart insulin syringe designed to provide real-time data on insulin administration. This innovation is significant as it aligns with the growing trend towards digital health solutions, potentially improving patient adherence and outcomes. The introduction of such technology not only enhances Becton Dickinson's product portfolio but also positions the company as a leader in the integration of digital tools within diabetes management.

In September 2025, Novo Nordisk (DK) entered a strategic partnership with a leading telehealth provider to enhance remote patient monitoring capabilities. This collaboration is crucial as it reflects the increasing importance of telehealth in chronic disease management, particularly for diabetes care. By integrating their insulin delivery systems with telehealth services, Novo Nordisk aims to provide a more comprehensive solution that addresses patient needs beyond just medication delivery.

In July 2025, Eli Lilly (US) expanded its manufacturing capabilities in Europe to meet the rising demand for insulin syringes. This expansion is indicative of the company's commitment to ensuring supply chain reliability and responsiveness to market fluctuations. By increasing production capacity, Eli Lilly not only strengthens its market position but also mitigates potential supply chain disruptions, which are increasingly critical in today's global market.

As of October 2025, current competitive trends in the Insulin Syringes Market are heavily influenced by digitalization, sustainability, and the integration of artificial intelligence. Strategic alliances are becoming more prevalent, enabling companies to pool resources and expertise to enhance product offerings. The competitive landscape is shifting from traditional price-based competition towards a focus on innovation, technology, and supply chain reliability. This evolution suggests that companies that prioritize these aspects will likely achieve a sustainable competitive advantage in the future.

Key Companies in the Insulin Syringes Market market include

Industry Developments

Future Outlook

Insulin Syringes Market Future Outlook

The Insulin Syringes Market is projected to grow at a 4.2% CAGR from 2024 to 2035, driven by increasing diabetes prevalence, technological advancements, and rising healthcare expenditure.

New opportunities lie in:

Expansion of smart insulin delivery devices
Development of eco-friendly syringe materials
Partnerships with telehealth platforms for remote patient monitoring

By 2035, the market is expected to achieve robust growth, reflecting evolving healthcare needs and technological innovations.

Market Segmentation

Insulin Syringes Market Disease Outlook

Type 1 Diabetes
Type 2 Diabetes

Insulin Syringes Market End-use Outlook

Hospitals & Clinics
Homecare Settings
Others

Insulin Syringes Market Syringe Size Outlook

3/10 CC Syringe (0.3ml)
1/2 CC Syringe (0.5ml)
1CC Syringe (1ml)
Others

Report Scope

MARKET SIZE 2024	1.844(USD Billion)
MARKET SIZE 2025	1.922(USD Billion)
MARKET SIZE 2035	2.901(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR)	4.2% (2024 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
Market Forecast Period	2025 - 2035
Historical Data	2019 - 2024
Market Forecast Units	USD Billion
Key Companies Profiled	Market analysis in progress
Segments Covered	Market segmentation analysis in progress
Key Market Opportunities	Integration of smart technology in Insulin Syringes Market enhances patient adherence and monitoring capabilities.
Key Market Dynamics	Rising demand for insulin syringes driven by increasing diabetes prevalence and advancements in injection technology.
Countries Covered	North America, Europe, APAC, South America, MEA